Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Companies Race To Withdraw ANDAs

Executive Summary

Industry consolidation may be a reason ANDA withdrawals have increased during GDUFA II.

You may also be interested in...



December ANDA Rush Is Largest In Two Years

December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.

December ANDA Rush Is Largest Monthly Haul In Two Years

However, the month may be losing its influence over the US FDA's annual submission total.

FDA Reports Millions In Unpaid GDUFA Fees

The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.

Related Content

Topics

UsernamePublicRestriction

Register

PS125556

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel